Manufacturer
ACCORD HEALTHCARE SDN.BHD.
Contents
Capecitabine
Indication
In combination w/ docetaxel for locally advanced or metastatic breast cancer after cytotoxic chemotherapy failure. Monotherapy for locally advanced or metastatic breast cancer after failure of taxane & anthracycline-containing chemotherapy regimen or for whom further anthracycline therapy is not indicated. Metastatic colorectal carcinoma. Adjuvant treatment following surgery of stage III (Duke's stage C) colon cancer. 1st-line treatment of advanced oesophagogastric cancer in combination w/ platinum-based agent.
Drug interaction
Altered coagulation parameter &/or bleeding w/ coumarin-derivative anticoagulants eg, warfarin & phenprocoumon. Increased phenytoin plasma conc. Increased plasma conc w/ Al & Mg hydroxide-containing antacid. Enhanced toxicity by leucovorin. Not to be administered concomitantly w/ sorivudine or analogues eg, brivudine.
ACCORD HEALTHCARE SDN.BHD.
Contents
Capecitabine
Indication
In combination w/ docetaxel for locally advanced or metastatic breast cancer after cytotoxic chemotherapy failure. Monotherapy for locally advanced or metastatic breast cancer after failure of taxane & anthracycline-containing chemotherapy regimen or for whom further anthracycline therapy is not indicated. Metastatic colorectal carcinoma. Adjuvant treatment following surgery of stage III (Duke's stage C) colon cancer. 1st-line treatment of advanced oesophagogastric cancer in combination w/ platinum-based agent.
Drug interaction
Altered coagulation parameter &/or bleeding w/ coumarin-derivative anticoagulants eg, warfarin & phenprocoumon. Increased phenytoin plasma conc. Increased plasma conc w/ Al & Mg hydroxide-containing antacid. Enhanced toxicity by leucovorin. Not to be administered concomitantly w/ sorivudine or analogues eg, brivudine.
Inquiry - INTACAPE 150 (Capecitabine Tablets USP 150 mg)